Dr Lal PathLabs Q4FY24: Revenue reaches Rs 545 crore, PAT Rs 86 crore

Dr. Lal PathLabs has announced its Q4 FY24. The company reported a rise of 49 percent in net profit at ₹84.5 crore, compared to ₹56.7 crore in the corresponding period last year. Its revenue from operations rose 11 percent to ₹545.5 crore, compared to ₹491 crore reported in the year-ago period. The number of samples tested grew 8.5 percent during the quarter and was up roughly 10 percent for the fiscal year.

The company’s board recommended a final dividend of ₹6 per equity share for FY24.

“Dr. Lal PathLabs remains dedicated to driving sustainable growth in response to the demand for dependable diagnostic services. We’re investing in an efficient, technology-enabled network to accommodate the growing volume of samples and enhance patient accessibility. Our strategic focus areas, including geographical expansion, portfolio diversification and digital transformation, are driving significant progress. By leveraging our unique strengths, such as DLPL and Suburban’s distinct USPs, we’re prioritizing network synergies as well as employing a physical mechanism to meet evolving consumer preferences,” said (Hony) Brig. Dr. Arvind Lal, Executive Chairman.

“As we navigate through the competitive landscape and pursue growth opportunities, our approach emphasizes both organic and inorganic opportunities, particularly in the untapped markets. Through continuous innovation, branding efforts, and prudent financial management, we’re dedicated to maintaining our leadership position and enhancing shareholder value.”

“We’re expanding our reach in core markets by strengthening our presence in Tier 3 and Tier 4 towns,” said Shankha Banerjee, Chief Executive Officer-designate, Dr. Lal PathLabs.
MB Bureau